Accordingly, this narrative review sought to examine the emerging insights into the pathophysiological mechanisms linking OSA to cardiovascular disease and to evaluate the potential of GLP-1 receptor agonists and SGLT2 inhibitors in attenuating cardiovascular risk among individuals with OSA. Here, SLC5A2 is linked to obstructive sleep apnea syndrome.